Wyeth Reduces Risk with Dyadem Software
Posted on: Thursday, 2 April 2009, 07:00 CDT
PHA-Pro is a software solution that delivers industry-standard Process Hazard Analysis (PHA) capabilities for the process industries. The PHA methodology is an integral part of a pharmaceutical manufacturer's Process Safety Management program and results in safer and more predictable production processes. Dyadem's PHA-Pro helps manage Risk Lifecycle Management processes, and was built to reflect the risk mitigation initiatives and operating environments of the various process industries. This is essential to optimizing work time, minimizing work stoppages, and reducing the potential for undesirable events, while improving the safety and quality of a given product for consumers.
With PHA-Pro being used across their global organization, Wyeth has integrated the knowledge and expertise of all departments into their PHA studies and provided the Environmental Health and Safety department visibility into the overall business process, making everyone at the company more aware of their global business and safety strategy. "We needed a systematic, methodical way to document our PHA studies," said
Having used PHA-Pro for many years, Wyeth has been able to continuously improve their risk management program. The easy configuration of templates, along with the application's industry-specific libraries and report-generating features have allowed Wyeth to focus on their business process and overall business strategy, instead of worrying about the consistency of their PHA studies. Since implementing PHA-Pro, Wyeth has been able to establish a best-practice platform which has proven to management the value of a consistent hazard review process across the network.
"Wyeth's commitment to safety and visibility for all departments are some of the reasons it has remained a leader in the pharmaceutical industry," said
About Dyadem
Dyadem is the market leader in Quality Lifecycle Management and Risk Lifecycle Management solutions. Dyadem provides software and services that empower companies to manage quality, mitigate risks, achieve regulatory compliance, plan for business continuity and improve profitability. Dyadem works with 85% of the Fortune 500 companies and serves the high tech & electronics, medical devices, oil and gas, chemical, automotive, pharmaceutical and aerospace and defense industries. For more information, visit www.dyadem.com
About Wyeth
Wyeth is a global leader in prescription pharmaceuticals, non-prescription consumer health care products, and pharmaceuticals for animal health. Wyeth's products are sold in more than 145 countries, and its product portfolio includes innovative treatments across a wide range of therapeutic areas. Wyeth's worldwide resources include 47,500 employees, manufacturing facilities on four continents, and a unique research and technology base encompassing small molecules, biopharmaceuticals, genetic engineering that will give us the next wave of innovative therapies, and vaccines. With this depth of resources, Wyeth will continue to lead the way in the development of novel therapies that address critical global health needs. For more information, visit www.wyeth.com.
For further information, contact: Text 100 Public Relations Kevin Doak 617.399.4931 dyadem@text100.comSOURCE Dyadem
Source: PR Newswire
Related Articles
- Pro-Pharmaceuticals' Management Outlines Strategic Initiatives
- European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
- Pro-Pharmaceuticals Enters Research Collaboration With University of Massachusetts Lowell
- Pro-Pharmaceuticals & Brigham and Women's Hospital Announce New Kidney Fibrosis Research Collaboration
- Pro-Pharmaceuticals Collaborates With Chemwerth to Scale-Up Production of DAVANAT(R) for Initial Marketing Needs
- Pro-Pharmaceuticals' Begins Process of New Drug Application Submission With the FDA for Co-Administration of DAVANAT(R) With 5-FU in Cancer Patients
- Pro-Pharmaceuticals Provides Corporate Update of 2006 Achievements and 2007 Objectives
- Pro-Pharmaceuticals Reports Second Quarter 2006 Results
- Pro-Pharmaceuticals Files Phase II Clinical Trial Protocol for First Line Treatment of Colorectal Cancer Patients; Regimen Includes DAVANAT(R) With Avastin(R), 5-FU & Leucovorin
- Pro-Pharmaceuticals Retains Dr. James T. Gourzis to Provide Clinical Management & Strategic Development of Its Europe-Based Phase III Colorectal Cancer Trial
User Comments (0)

RSS Feeds